Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies 2019

Jennifer Jones's Biography



Jennifer Jones, Staff Clinician, Molecular Immunogenetics & Vaccine Research Section, National Cancer Institute (NCI)

Dr. Jones is a Radiation Oncologist at the National Institutes of Health, who is developing, refining, and applying advanced high-resolution flow cytometric methods to the characterization of EV subsets. She initiated/cofounded the international ISEV-ISAC-ISTH EV Flow Cytometry Working Group, to support the development of consensus best practices and standardization methods for the field. The ultimate goal of her research is to develop a new class of EV-based biomarkers (and methods for anlyzing those EVs) that will enable adaptve therapeutic strategies, where individual patient treatments are customized based on early responses to treatment.

Jennifer Jones Image

Mt-SEA Pipeline: High Throughput Flow Cytometric Analysis of Exosomes in Clinical Biofluids

Wednesday, 27 March 2019 at 09:00

Add to Calendar ▼2019-03-27 09:00:002019-03-27 10:00:00Europe/LondonMt-SEA Pipeline: High Throughput Flow Cytometric Analysis of Exosomes in Clinical BiofluidsLiquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Because Extracellular Vesicles (EVs) carry surface receptors that are characteristic of their cells of origin, EVs have tremendous potential as non-invasive biomarkers for diagnosis, risk-stratification, treatment selection, and treatment monitoring. We developed a first-in-class pipeline to characterize EV heterogeneity and provide high-sensitivity quantification of informative EVs in biofluids before, during, and after treatment. By combining multiplex assays with high-resolution, single EV flow cytometric methods together into a Mutiplex-to-Single EV Analysis (Mt-SEA) pipeline, we are able to characterize a broad range of relevant EV subsets, while also accurately measuring the concentration of specific EV populations.  Detection of tumor-associated EVs and detection of EV repertoire changes during treatment paves the way to future evaluation of EVs as as biomarkers for use in personalized, adaptive therapies.


Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonLiquid Biopsies 2019Liquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com